Reference 1. Merck Canada Inc. KEYTRUDA® Product Monograph. July 20, 2023.
CA-KEY-01241
KEYTRUDA® has been issued marketing authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization.
KEYTRUDA® is indicated for:
KEYTRUDA® has been issued marketing authorization without conditions for:
Clinical use:
The safety and efficacy of KEYTRUDA® has not been established for pediatric patients with conditions other than relapsed or refractory cHL, or relapsed or refractory PMBCL, or melanoma (Stage IIB or IIC).
Geriatrics (>65 years of age): No overall differences in safety or efficacy were reported between elderly patients (65 years and over) and younger patients (less than 65 years). Limited safety and efficacy information is available for KEYTRUDA® in cHL ≥65 years of age (n=20).
Relevant warnings and precautions:
For more information:
Please consult the Product Monograph for important information regarding adverse reactions, drug interactions, and dosing information which have not been discussed in this piece.
The Product Monograph is also available by calling us at 1-800-567-2594 or by email at medinfocanada@merck.com.
PD-L1=programmed death-ligand 1.